Biohaven Pharma (BHVN) Q2 NURTEC ODT Sales Rise to $93M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biohaven Pharmaceuticals (BHVN) Gains Following Sales Surge for Migraine Drug NURTEC ODT
July 7, 2021 11:36 AM EDTBiohaven Pharmaceutical (NYSE: BHVN) shares are gaining 11% following the announcement of preliminary Q2 results: net product revenue of NURTEC ODT (rimegepant) came in at $93M, increasing 119% Q/Q. Total prescriptions since the product launch exceeded 750,000 across 38,000 unique subscribers.
The results have far outpaced analysts' expectations consensus sales figures hovered around $50-55 million.
Commenting on the strong performance, the companys CCO, BJ... More
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $130 at Cowen on Nurtec Momentum
July 7, 2021 10:38 AM EDTCowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $130.00 (from $90.00) while maintaining an Outperform rating.
The analyst commented, "Preliminary Nurtec revenues reached $93MM in Q2, substantially above our and the Street's $55MM. Although we are unsure... More
